Auner Lab

Contact


Dr Holger Auner

  • Clinical Senior Lecturer and Honorary Consultant in Haematology
  • Head of Translational Research at the Centre
  • Group Leader - Cancer Cell Protein Metabolism

+44 (0)20 3313 4017
holger.auner04@imperial.ac.uk

Areas of research


Proteotoxic stress and metabolism

Myeloma cells are characterised by a unique sensitivity to inhibitors of the proteasome, which is responsible for the controlled degradation of most cellular proteins that have become damaged or are otherwise unwanted. Nevertheless, resistance to proteasome inhibitors occurs in essentially all patients to varying degrees. Accumulation of misfolded proteins in the endoplasmic reticulum (ER), which triggers proteotoxic ‘ER stress’, is widely believed to be the main mechanism of action of proteasome inhibitors. However, data from our lab and other research groups suggest complex interactions between proteasomal protein degradation and multiple metabolic processes. Our aim is to find metabolic and proteostatic vulnerabilities that we can exploit therapeutically.


Tissue biophysics in myeloma biology

Several important aspects of cancer cell biology are influenced by mechanical cues from the surrounding tissue. In particular, mechanical interactions and matrix remodelling have been shown to govern cancer cell metabolism. Tissue stiffness also impacts on normal haematopoiesis, and mechanical cues are known to modulate therapeutic responses. Moreover, we have shown that proteostasis-targeting drugs can alter tissue physical properties. We aim to understand how tissue stiffness and nutrient availability act together to rewire metabolic networks and regulate drug responses in myeloma.


Citation

BibTex format

@article{Tornatore:2019:10.1111/bjh.15569,
author = {Tornatore, L and Capece, D and D'Andrea, D and Begalli, F and Verzella, D and Bennett, J and Acton, G and Campbell, EA and Kelly, J and Tarbit, M and Adams, N and Bannoo, S and Leonardi, A and Sandomenico, A and Raimondo, D and Ruvo, M and Chambery, A and Oblak, M and Al-Obaidi, MJ and Kaczmarski, RS and Gabriel, I and Oakervee, HE and Kaiser, MF and Wechalekar, A and Benjamin, R and Apperley, JF and Auner, HW and Franzoso, G},
doi = {10.1111/bjh.15569},
journal = {British Journal of Haematology},
pages = {588--592},
title = {Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma},
url = {http://dx.doi.org/10.1111/bjh.15569},
volume = {185},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Tornatore,L
AU - Capece,D
AU - D'Andrea,D
AU - Begalli,F
AU - Verzella,D
AU - Bennett,J
AU - Acton,G
AU - Campbell,EA
AU - Kelly,J
AU - Tarbit,M
AU - Adams,N
AU - Bannoo,S
AU - Leonardi,A
AU - Sandomenico,A
AU - Raimondo,D
AU - Ruvo,M
AU - Chambery,A
AU - Oblak,M
AU - Al-Obaidi,MJ
AU - Kaczmarski,RS
AU - Gabriel,I
AU - Oakervee,HE
AU - Kaiser,MF
AU - Wechalekar,A
AU - Benjamin,R
AU - Apperley,JF
AU - Auner,HW
AU - Franzoso,G
DO - 10.1111/bjh.15569
EP - 592
PY - 2019///
SN - 1365-2141
SP - 588
TI - Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma
T2 - British Journal of Haematology
UR - http://dx.doi.org/10.1111/bjh.15569
UR - https://www.ncbi.nlm.nih.gov/pubmed/30255568
UR - http://hdl.handle.net/10044/1/70571
VL - 185
ER -